Current drugs treat bronchospasm and inflammation-to a degree

• They relieve symptoms and are expensive.

• Very sick patients require high dosages of steroids

• Most of the inhaled drug combinations contain a steroid and act via receptors.

• Despite these drugs’ availability, COPD is progressive in many patients and exacerbations still occur. Disease progression is often not halted

• The presently-used drugs ameliorate symptoms but are not disease modifying.

​

The Artin Bioscience Approach for COPD is a non-steroid dual drug treatment that is expected to stop disease progression, targeting the smoldering steroid and unresponsive inflammation.

• This new  treatment is expected to decrease the number of inflammatory cells in the lung, inhibit fibrosis and cause lung vessel dilatation.

• This approach is unique as it targets steroid-unresponsive mechanisms of inflammation.

• Responding COPD patients should see stabilization of their disease, improved quality of life and a decrease in the number of exacerbations.

• The new treatment provides an anti-viral component that benefits patients that commonly are diagnosed with viral infections that cause COPD exacerbations.

• ​Expected to be effective for other respiratory diseases, such as Asthma.

.